Scarica l'app Stockscreener
7.72
4.22%
-0.34
Dopo l'orario di chiusura:
7.71
-0.010
-0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$8.06
Aprire:
$7.87
Volume 24 ore:
8.79M
Relative Volume:
0.88
Capitalizzazione di mercato:
$8.18B
Reddito:
$140.98M
Utile/perdita netta:
$-854.60M
Rapporto P/E:
-9.0398
EPS:
-0.854
Flusso di cassa netto:
$-299.31M
1 W Prestazione:
-5.74%
1M Prestazione:
+3.07%
6M Prestazione:
-3.62%
1 anno Prestazione:
+200.39%
Intervallo 1D:
$7.64
$7.89
Intervallo di 1 settimana:
$7.64
$8.37
Portata 52W:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.72 | 8.54B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | BTIG Research | Buy |
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunitybio Inc Borsa (IBRX) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Investors to Connect - ACCESS Newswire
ImmunityBio Confirms Trial Strength For Anktiva In Bladder Cancer - Stocktwits
U.S. Presidential Envoy Joins Albania’s Religious Leaders to Honor Mother Teresa as Bektashi Order Announces Signed American Cancer-Care Partnership - Albanian Daily News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ImmunityBio, Inc. Tokenized Stock (Robinhood) to British Pound Sterling Price Today | Live IBRX to GBP Converter & Exchange Rate - CryptoRank
ImmunityBio, Inc. Tokenized Stock (Robinhood) to Indonesian Rupiah Price Today | Live IBRX to IDR Converter & Exchange Rate - CryptoRank
ImmunityBio, Inc. Tokenized Stock (Robinhood) to South Korean Won Price Today | Live IBRX to KRW Converter & Exchange Rate - CryptoRank
ImmunityBio, Inc. Tokenized Stock (Robinhood) to Canadian Dollar Price Today | Live IBRX to CAD Converter & Exchange Rate - CryptoRank
ImmunityBio, Inc. Tokenized Stock (Robinhood) to United States Dollar Price Today | Live IBRX to USD Converter & Exchange Rate - CryptoRank
ImmunityBio, Inc. Tokenized Stock (Robinhood) to Euro Price Today | Live IBRX to EUR Converter & Exchange Rate - CryptoRank
ImmunityBio, Inc. Tokenized Stock (Robinhood) to Vietnamese Dong Price Today | Live IBRX to VND Converter & Exchange Rate - CryptoRank
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
2026-09-06 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation | NDAQ:IBRX | Press Release - Stockhouse
IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Growth Catalyst - Stocktwits
IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease - Stocktwits
IBRX Stock Slips Overnight: Founder Teases Turkey Push, Says AI Cancer Cell Robot Is ‘Almost There’ - Stocktwits
IBRX|Immunitybio Inc|Price:8.080|Chg%:-0.110 - TradingKey
Historical Data for ImmunityBio, Inc. Tokenized Stock (Robinhood) in USD - CryptoRank
ImmunityBio, Inc. Tokenized Stock (Robinhood) Exchanges IBRX Markets | Buy & Sell & Trade - CryptoRank
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report? - Yahoo Finance
ImmunityBio: None Of The Moonshots Is Priced In (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IBRX to IDR: ImmunityBio, Inc. • Robinhood Token Price in Indonesian Rupiah - CoinGecko
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Connect - ACCESS Newswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ImmunityBio, Inc. Tokenized Stock (Robinhood) Closing Price (USD)Quarterly - CryptoRank
ImmunityBio Stock Short Interest Falls to 31.8% - Quiver Quantitative
ImmunityBio: ANKTIVA Is Real, The Valuation Isn't (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer - Eastern Progress
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitContact Kessler Topaz Meltzer & Check, LLP - Morningstar
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
ImmunityBio (NASDAQ:IBRX): What Could Shape Its Next Move? - Kalkine Media
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Patrick Soon-Shiong to Thomas Ichim: Thanks for Sharing Important Difference Between Il-2 and Il-15 - Oncodaily
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Class A - The National Law Review
ImmunityBio (IBRX) Shares Moved, What Is Behind The Fresh Attention? - Sahm
147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc. - MarketBeat
Does Adding Jim Yong Kim to Leadership Shift ImmunityBio’s Global Strategy Narrative (IBRX)? - simplywall.st
IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales - Stocktwits
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast - 24/7 Wall St.
ImmunityBio, Inc. (IBRX) options chain - Yahoo Finance UK
ImmunityBio, Inc. (IBRX) Investor Outlook: Exploring A 70% Upside Potential - DirectorsTalk Interviews
Jim Yong Kim Joins ImmunityBio as Vice Chairman - Oncodaily
ImmunityBio, Inc. • Robinhood Token (IBRX) Price Prediction for 2026 to 2031 - bybit.com
Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus - FinancialContent
ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach - Sahm
ImmunityBio Names Former World Bank President Jim Yong Kim Vice Chairman - citybiz
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):